To date, no effective target treatments have been approved for HER2-negative BC patients, since several studies have demonstrated a beneficial effect of the addition of trastuzumab to chemotherapy only in tumors with HER2 overexpression [23,24,25]. This evidence concerns the gene ERBB2 and breast cancer.